Meeder Advisory Services Inc. Acquires New Holdings in Boston Scientific Corporation $BSX

Meeder Advisory Services Inc. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 36,679 shares of the medical equipment provider's stock, valued at approximately $1,565,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Main Street Financial Solutions LLC lifted its position in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock valued at $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC boosted its stake in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock worth $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC increased its holdings in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock worth $763,000 after purchasing an additional 2,556 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Mizuho dropped their price target on Boston Scientific from $90.00 to $70.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 15th. Raymond James Financial reissued an "outperform" rating and issued a $57.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Canaccord Genuity Group cut their target price on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Citigroup reduced their price target on Boston Scientific from $70.00 to $61.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research note on Thursday, May 28th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $71.62.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger acquired 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 in the last 90 days. Corporate insiders own 0.34% of the company's stock.

Boston Scientific Price Performance

NYSE:BSX opened at $52.02 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock's 50-day simple moving average is $46.22 and its 200 day simple moving average is $58.22. The company has a market cap of $75.39 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.10 and a beta of 0.56. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the company posted $0.75 earnings per share. Boston Scientific's revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source